Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medical Informatics and Decision Making
Published in: BMC Medical Informatics and Decision Making 1/2018

Open Access 01-12-2018 | Research article

Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting

Authors: Rita Kukafka, Jiaqi Fang, Alejandro Vanegas, Thomas Silverman, Katherine D. Crew

Published in: BMC Medical Informatics and Decision Making | Issue 1/2018

Login to get access

Abstract

Background

Breast cancer chemoprevention can reduce breast cancer incidence in high-risk women; however, chemoprevention is underutilized in the primary care setting. We conducted a pilot study of decision support tools among high-risk women and their primary care providers (PCPs).

Methods

The intervention included a decision aid (DA) for high-risk women, RealRisks, and a provider-centered tool, Breast Cancer Risk Navigation (BNAV). Patients completed validated surveys at baseline, after RealRisks and after their PCP clinical encounter or at 6-months. Referral for high-risk consultation and chemoprevention uptake were assessed via the electronic health record. The primary endpoint was accuracy of breast cancer risk perception at 6-months.

Results

Among 40 evaluable high-risk women, median age was 64.5 years and median 5-year breast cancer risk was 2.19%. After exposure to RealRisks, patients demonstrated an improvement in accurate breast cancer risk perceptions (p = 0.02), an increase in chemoprevention knowledge (p < 0.01), and 24% expressed interest in taking chemoprevention. Three women had a high-risk referral, and no one initiated chemoprevention. Decisional conflict significantly increased from after exposure to RealRisks to after their clinical encounter or at 6-months (p < 0.01). Accurate breast cancer risk perceptions improved and was sustained at 6-months or after clinical encounters. We discuss the side effect profile of chemoprevention and the care pathway when RealRisks was introduced to understand why patients experienced increased decision conflict.

Conclusion

Future interventions should carefully link the use of a DA more proximally to the clinical encounter, investigate timed measurements of decision conflict and improve risk communication, shared decision making, and chemoprevention education for PCPs. Additional work remains to better understand the impact of decision aids targeting both patients and providers.

Trial registration

ClinicalTrials.​gov Identifier: NCT02954900 November 4, 2016 Retrospectively registered.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.PubMedCrossRef
2.
3.
Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541–8.PubMedCrossRef
4.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and bowel project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.PubMedCrossRef
5.
Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67–75.PubMedPubMedCentralCrossRef
6.
Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.PubMedCrossRef
7.
Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.PubMedCrossRef
8.
Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2013;158(8):604–14.PubMedCrossRef
9.
10.
11.
Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27(19):3235–58.PubMedPubMedCentralCrossRef
12.
Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28(18):3090–5.PubMedPubMedCentralCrossRef
13.
Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):575–90.PubMedCrossRef
14.
Fagerlin A, Dillard AJ, Smith DM, et al. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat. 2011;127(3):681–8.PubMedPubMedCentralCrossRef
15.
Owens WL, Gallagher TJ, Kincheloe MJ, Ruetten VL. Implementation in a large health system of a program to identify women at high risk for breast cancer. J Oncol Pract. 2011;7(2):85–8.PubMedPubMedCentralCrossRef
16.
Kaplan CP, Livaudais-Toman J, Tice JA, et al. A randomized, controlled trial to increase discussion of breast cancer in primary care. Cancer Epidemiol Biomark Prev. 2014;23(7):1245–53.CrossRef
17.
Legare F, Robitaille H, Gane C, Hebert J, Labrecque M, Rousseau F. Improving decision making about genetic testing in the clinic: an overview of effective knowledge translation interventions. PLoS One. 2016;11(3):e0150123.PubMedPubMedCentralCrossRef
18.
Holmberg C, Bandos H, Fagerlin A, et al. NRG oncology/National Surgical Adjuvant Breast and bowel project decision-making Project-1 results: decision making in breast Cancer risk reduction. Cancer Prev Res (Phila). 2017;10(11):625–34.PubMedCentralCrossRef
19.
Korfage IJ, Fuhrel-Forbis A, Ubel PA, et al. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. Breast Cancer Res. 2013;15(5):R74.PubMedPubMedCentralCrossRef
20.
Meiser B, Wong WKT, Peate M, Julian-Reynier C, Kirk J, Mitchell G. Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review. Hered Cancer Clin Pract. 2017;15:14.PubMedPubMedCentralCrossRef
21.
Coe AM, Ueng W, Vargas JM, et al. Usability testing of a web-based decision aid for breast Cancer risk assessment among multi-ethnic women. AMIA Annu Symp Proc. 2016;2016:411–20.PubMed
22.
McGuinness J, Ueng W, Trivedi MS, et al. Factors associated with false positive results on screening mammography in a population of predominantly Hispanic women (in press). Cancer Epidemiol Biomark Prev. 2017.
23.
Kukafka R, Yi H, Xiao T, et al. Why breast Cancer risk by the numbers is not enough: evaluation of a decision aid in multi-ethnic, low-numerate women. J Med Internet Res. 2015;17(7):e165.PubMedPubMedCentralCrossRef
24.
A I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991.
25.
Yi H, Xiao T, Thomas PS, et al. Barriers and facilitators to patient-provider communication when discussing breast Cancer risk to aid in the development of decision support tools. AMIA Annu Symp Proc. 2015;2015:1352–60.PubMedPubMedCentral
26.
Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004;36(8):588–94.PubMed
27.
Lipkus IM, Samsa G, Rimer BK. General performance on a numeracy scale among highly educated samples. Med Decis Mak. 2001;21(1):37–44.CrossRef
28.
Mandelblatt J, Kaufman E, Sheppard VB, et al. Breast cancer prevention in community clinics: will low-income Latina patients participate in clinical trials? Prev Med. 2005;40(6):611–8.PubMedCrossRef
29.
Williams GC, Rodin GC, Ryan RM, Grolnick WS, Deci EL. Autonomous regulation and long-term medication adherence in adult outpatients. Health Psychol. 1998;17(3):269–76.PubMedCrossRef
30.
Lipkus IM, Kuchibhatla M, McBride CM, et al. Relationships among breast cancer perceived absolute risk, comparative risk, and worries. Cancer Epidemiol Biomarkers Prev. 2000;9(9):973–5.PubMed
31.
Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293(14):1729–36.PubMedCrossRef
32.
Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med. 1991;114(8):657–61.PubMedCrossRef
33.
O'Connor AM. Validation of a decisional conflict scale. Med Decis Mak. 1995;15(1):25–30.CrossRef
34.
Kreuter MW, Strecher VJ. Changing inaccurate perceptions of health risk: results from a randomized trial. Health Psychol. 1995;14(1):56–63.PubMedCrossRef
35.
Daly MB, Lerman CL, Ross E, Schwartz MD, Sands CB, Masny A. Gail model breast cancer risk components are poor predictors of risk perception and screening behavior. Breast Cancer Res Treat. 1996;41(1):59–70.PubMedCrossRef
36.
Stalmeier PF, Unic IJ, Verhoef LC, Van Daal WA. Evaluation of a shared decision making program for women suspected to have a genetic predisposition to breast cancer: preliminary results. Med Decis Mak. 1999;19(3):230–41.CrossRef
37.
Graves KD, Huerta E, Cullen J, et al. Perceived risk of breast cancer among Latinas attending community clinics: risk comprehension and relationship with mammography adherence. Cancer Causes Control. 2008;19(10):1373–82.PubMedPubMedCentralCrossRef
38.
LeBlanc A, Kenny DA, O'Connor AM, Legare F. Decisional conflict in patients and their physicians: a dyadic approach to shared decision making. Med Decis Mak. 2009;29(1):61–8.CrossRef
39.
Izadi S, Pachur T, Wheeler C, McGuire J, Waters EA. Spontaneous mental associations with the words "side effect": implications for informed and shared decision making. Patient Educ Couns. 2017;100(10):1928–33.PubMedPubMedCentralCrossRef
40.
Hoerger M, Scherer LD, Fagerlin A. Affective forecasting and medication decision making in breast-cancer prevention. Health Psychol. 2016;35(6):594–603.PubMedPubMedCentralCrossRef
41.
Waters EA, Weinstein ND, Colditz GA, Emmons K. Explanations for side effect aversion in preventive medical treatment decisions. Health Psychol. 2009;28(2):201–9.PubMedPubMedCentralCrossRef
42.
Waters EA, Weinstein ND, Colditz GA, Emmons KM. Reducing aversion to side effects in preventive medical treatment decisions. J Exp Psychol Appl. 2007;13(1):11–21.PubMedCrossRef
43.
Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004;22(24):4951–7.PubMedCrossRef
44.
Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch HT, Narod S. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Familial Cancer. 2005;4(2):97–103.PubMedCrossRef
45.
Salant T, Ganschow PS, Olopade OI, Lauderdale DS. "why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006;21(7):779–85.PubMedPubMedCentralCrossRef
46.
Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med. 2005;3(3):242–7.PubMedPubMedCentralCrossRef
47.
Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8(7):580–5.PubMedCrossRef
48.
Stacey D, O'Connor AM, DeGrasse C, Verma S. Development and evaluation of a breast cancer prevention decision aid for higher-risk women. Health Expect. 2003;6(1):3–18.PubMedPubMedCentralCrossRef
49.
Melnikow J, Paterniti D, Azari R, et al. Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer. 2005;103(10):1996–2005.PubMedCrossRef
50.
51.
Anderson CJ. The psychology of doing nothing: forms of decision avoidance result from reason and emotion. Psychol Bull. 2003;129(1):139–67.PubMedCrossRef
52.
Luce MF. Choosing to avoid: coping with negatively emotion-laden consumer decisions. J Consum Res. 1998;24:409–33.CrossRef
53.
Martinez KA, Fagerlin A, Witteman HO, Holmberg C, Hawley ST. What matters to women when making decisions about breast Cancer chemoprevention? Patient. 2016;9(2):149–59.PubMedPubMedCentralCrossRef
54.
Misra-Hebert AD, Kattan MW. Comment on: decisional conflict, regret, and the burden of rational decision making. Med Decis Mak. 2017;37(4):E360–1.CrossRef
55.
Vickers AJ. Response to "comment on: decisional conflict, regret, and the burden of rational decision making". Med Decis Mak. 2017;37(4):E362.CrossRef
56.
Vickers AJ. Decisional conflict, regret, and the burden of rational decision making. Med Decis Mak. 2017;37(1):3–5.CrossRef
57.
O'Connor AM, Fiset V, DeGrasse C, et al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr. 1999;(25):67–80.
58.
Holmberg C, Waters EA, Whitehouse K, Daly M, McCaskill-Stevens W. My lived experiences are more important than your probabilities: the role of individualized risk estimates for decision making about participation in the study of tamoxifen and Raloxifene (STAR). Med Decis Mak. 2015;35(8):1010–22.CrossRef
59.
Reyna VF. A theory of medical decision making and health: fuzzy trace theory. Med Decis Mak. 2008;28(6):850–65.CrossRef
60.
Finucane ML, Alhakami A, Slovic P, J SM. The affect heuristic in judgments of risks and benefits. J Behav Decis Mak. 2000;13(1):1–17.CrossRef
61.
Metadata
Title
Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting
Authors
Rita Kukafka
Jiaqi Fang
Alejandro Vanegas
Thomas Silverman
Katherine D. Crew
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medical Informatics and Decision Making / Issue 1/2018
Electronic ISSN: 1472-6947
DOI
https://doi.org/10.1186/s12911-018-0716-5

Other articles of this Issue 1/2018

BMC Medical Informatics and Decision Making 1/2018 Go to the issue

Research article

Patient facing decision support system for interpretation of laboratory test results

Research article

Using data-driven sublanguage pattern mining to induce knowledge models: application in medical image reports knowledge representation

Research article

The readiness of hospital pharmacists in Kuwait to practise evidence-based medicine: a cross-sectional study

Research article

Promoting exercise training and physical activity in daily life: a feasibility study of a virtual group intervention for behaviour change in COPD

Research article

Combining EEG signal processing with supervised methods for Alzheimer’s patients classification

Research article

Combining information from a clinical data warehouse and a pharmaceutical database to generate a framework to detect comorbidities in electronic health records